Table 2.
Genetic aberration analysis
| Total (n = 928) | NSCLC (n = 683) | SCLC (n = 129) | ||||
|---|---|---|---|---|---|---|
| Detection rate (%) | Positive rate (%) | Detection rate (%) | Positive rate (%) | Detection rate (%) | Positive rate (%) | |
| EGFR | 242 (26.1) | 121 (50.0) | 204 (29.9) | 100 (49.0) | 18 (14.0) | 10 (55.6) |
| ALK | 111 (12.0) | 4 (3.6) | 95 (13.9) | 3 (3.2) | 7 (5.4) | 0 |
| c‐MET | 11 (1.2) | 3 (27.3) | 10 (1.5) | 3 (30.0) | 0 | 0 |
| ROS1 | 26 (2.8) | 5 (19.2) | 25 (3.7) | 5 (20.0) | 0 | 0 |
| RET | 3 (0.3) | 0 | 3 (0.4) | 0 | 0 | 0 |
ALK, anaplastic lymphoma kinase; c‐MET, MET proto‐oncogene; EGFR, epidermal growth factor receptor; NSCLC, non‐small cell lung cancer; RET, RET proto‐oncogene; ROS1, c‐ros oncogene 1; SCLC, small cell lung cancer.